Recently, the CCND1-CDK4/6-RB molecular pathway has been investigated as a useful target in increasing the clinical benefit of ER+, HER2- breast cancer patients on first-line hormonal therapy; this constitutive pathway controls and governs whether a cell move on or arrests at the G1-S phase (140, 141). Here, ERBB2 is linked to breast carcinoma.